Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study
Open Access
- 3 August 2016
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 7, 235
Abstract
Background: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). Methods: Under this prism, we performed a systematic review of the literature for all relevant articles in order to evaluate the efficacy, safety, and possible clinical role of AZL-M in hypertensive diabetic patients. Results: AZL-M was found to be more effective in terms of reducing indices of blood pressure over alternative ARBs or angiotensin-converting enzyme (ACE) inhibitors with minimal side effects. Preclinical studies have established pleiotropic effects for AZL-M beyond its primary antihypertensive role through differential gene expression, up-regulation of membrane receptors and favorable effect on selective intracellular biochemical and pro-atherosclerotic pathways. Conclusion: Indirect but accumulating evidence from recent literature supports the efficacy and safety of AZL-M among diabetic patients. However, no clinical data exist to date that evince a beneficial role of AZL-M in patients with metabolic disorders on top of its antihypertensive effect. Further clinical studies are warranted to assess the pleiotropic cardiometabolic benefits of AZL-M that are derived from preclinical research.Keywords
This publication has 45 references indexed in Scilit:
- Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registryBMC Cardiovascular Disorders, 2016
- Cerebrovasculoprotective effects of azilsartan medoxomil in diabetesTranslational Research, 2014
- Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramiprilJournal of Human Hypertension, 2013
- Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertensionExpert Opinion on Drug Metabolism & Toxicology, 2012
- Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan MedoxomilThe American Journal of Medicine, 2012
- Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic HypertensionHypertension, 2012
- Cardiovascular Outcomes in Framingham Participants With DiabetesHypertension, 2011
- The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood PressureThe Journal of Clinical Hypertension, 2011
- Prognostic significance of ambulatory blood pressure in hypertensive patients with history of cardiovascular diseaseBlood Pressure Monitoring, 2008
- Preserving renal function in adults with hypertension and diabetes: A consensus approachAmerican Journal of Kidney Diseases, 2000